1.Korean red ginseng prevents ethanol-induced hepatotoxicity in isolated perfused rat liver.
Hye Min PARK ; Shang Jin KIM ; Hyeon Kyu GO ; Gi Beum KIM ; Sung Zoo KIM ; Jin Shang KIM ; Hyung Sub KANG
Korean Journal of Veterinary Research 2011;51(2):159-164
Alcohol abuse and its medical and social consequences are a major health problem in many areas of the world. Korean red ginseng (KRG) has been traditionally used for the treatment of liver disease. This study was conducted to evaluate the hepatoprotective effects of KRG against hepatotoxicity in Sprague-Dawley rats treated with ethanol (EtOH). Administration of EtOH for 20 days induced significant changes in serum biochemical parameters (aspartate aminotransferase, alanine transaminase, and glucose) accompanied by histological changes in the liver tissue. Treatment with KRG prior to administration of EtOH inhibited the EtOH-induced biochemical and histological changes of the liver. In perfused rat livers, administration of EtOH caused an increase in lactate dehydrogenase (LDH) release into the perfusate and activated the pro-apoptotic Bax protein but inhibited the anti-apoptotic Bcl-2 protein. Pretreatment with KRG prior to administration of EtOH decreased the EtOH-induced LDH release and inhibition of Bcl-2 protein. These results suggest that KRG exerts anti-apoptotic effects and alleviated EtOH-induced liver injury in rats.
Alanine Transaminase
;
Alcoholism
;
Animals
;
bcl-2-Associated X Protein
;
Ethanol
;
L-Lactate Dehydrogenase
;
Liver
;
Liver Diseases
;
Panax
;
Rats
;
Rats, Sprague-Dawley
2.PLGA Microspheres Containing Hydrophobically Modified Magnesium Hydroxide Particles for Acid NeutralizationMediated Anti-Inflammation
Joon-Kyu KIM ; Eun-Jin GO ; Kyoung-Won KO ; Hyeon-Ji OH ; Jieun HAN ; Dong Keun HAN ; Wooram PARK
Tissue Engineering and Regenerative Medicine 2021;18(4):613-522
BACKGROUND:
Poly(lactic-co-glycolic acid) (PLGA) microspheres have been actively used in various pharmaceutical formulations because they can sustain active pharmaceutical ingredient release and are easy to administer into the body using a syringe. However, the acidic byproducts produced by the decomposition of PLGA cause inflammatory reactions in surrounding tissues, limiting biocompatibility. Magnesium hydroxide (MH), an alkaline ceramic, has attracted attention as a potential additive because it has an acid-neutralizing effect.
METHODS:
To improve the encapsulation efficiency of hydrophilic MH, the MH particles were capped with hydrophobic ricinoleic acid (RA-MH). PLGA microspheres encapsulated with RA-MH particles were manufactured by the O/W method. To assess the in vitro cytotoxicity of the degradation products of PLGA, MH/PLGA, and RA-MH/PLGA microspheres, CCK-8 and Live/Dead assays were performed with NIH-3T3 cells treated with different concentrations of their degradation products. in vitro anti-inflammatory effect of RA-MH/PLGA microspheres was evaluated with quantitative measurement of pro-inflammatory cytokines.
RESULTS:
The synthesized RA-MH was encapsulated in PLGA microspheres and displayed more than four times higher loading content than pristine MH. The PLGA microspheres encapsulated with RA-MH had an acid-neutralizing effect better than that of the control group. In an in vitro cell experiment, the degradation products obtained from RA-MH/PLGA microspheres exhibited higher biocompatibility than the degradation products obtained from PLGA microspheres. Additionally, the RA-MH/PLGA microsphere group showed an excellent anti-inflammatory effect.
CONCLUSION
Our results proved that RA-MH-encapsulated PLGA microspheres showed excellent biocompatibility with an anti-inflammatory effect. This technology can be applied to drug delivery and tissue engineering to treat various incurable diseases in the future.
3.PLGA Microspheres Containing Hydrophobically Modified Magnesium Hydroxide Particles for Acid NeutralizationMediated Anti-Inflammation
Joon-Kyu KIM ; Eun-Jin GO ; Kyoung-Won KO ; Hyeon-Ji OH ; Jieun HAN ; Dong Keun HAN ; Wooram PARK
Tissue Engineering and Regenerative Medicine 2021;18(4):613-522
BACKGROUND:
Poly(lactic-co-glycolic acid) (PLGA) microspheres have been actively used in various pharmaceutical formulations because they can sustain active pharmaceutical ingredient release and are easy to administer into the body using a syringe. However, the acidic byproducts produced by the decomposition of PLGA cause inflammatory reactions in surrounding tissues, limiting biocompatibility. Magnesium hydroxide (MH), an alkaline ceramic, has attracted attention as a potential additive because it has an acid-neutralizing effect.
METHODS:
To improve the encapsulation efficiency of hydrophilic MH, the MH particles were capped with hydrophobic ricinoleic acid (RA-MH). PLGA microspheres encapsulated with RA-MH particles were manufactured by the O/W method. To assess the in vitro cytotoxicity of the degradation products of PLGA, MH/PLGA, and RA-MH/PLGA microspheres, CCK-8 and Live/Dead assays were performed with NIH-3T3 cells treated with different concentrations of their degradation products. in vitro anti-inflammatory effect of RA-MH/PLGA microspheres was evaluated with quantitative measurement of pro-inflammatory cytokines.
RESULTS:
The synthesized RA-MH was encapsulated in PLGA microspheres and displayed more than four times higher loading content than pristine MH. The PLGA microspheres encapsulated with RA-MH had an acid-neutralizing effect better than that of the control group. In an in vitro cell experiment, the degradation products obtained from RA-MH/PLGA microspheres exhibited higher biocompatibility than the degradation products obtained from PLGA microspheres. Additionally, the RA-MH/PLGA microsphere group showed an excellent anti-inflammatory effect.
CONCLUSION
Our results proved that RA-MH-encapsulated PLGA microspheres showed excellent biocompatibility with an anti-inflammatory effect. This technology can be applied to drug delivery and tissue engineering to treat various incurable diseases in the future.
4.Randomized trial of subfascial infusion of ropivacaine for early recovery in laparoscopic colorectal cancer surgery.
Sang Hyun LEE ; Woo Seog SIM ; Go Eun KIM ; Hee Cheol KIM ; Joo Hyun JUN ; Jin Young LEE ; Byung Seop SHIN ; Heejin YOO ; Sin Ho JUNG ; Joungyoun KIM ; Seung Hyeon LEE ; Deok Kyu YO ; Yu Ri NA
Korean Journal of Anesthesiology 2016;69(6):604-613
BACKGROUND: There is a need for investigating the analgesic method as part of early recovery after surgery tailored for laparoscopic colorectal cancer (LCRC) surgery. In this randomized trial, we aimed to investigate the analgesic efficacy of an inverse ‘v’ shaped bilateral, subfascial ropivacaine continuous infusion in LCRC surgery. METHODS: Forty two patients undergoing elective LCRC surgery were randomly allocated to one of two groups to receive either 0.5% ropivacaine continuous infusion at the subfascial plane (n = 20, R group) or fentanyl intravenous patient controlled analgesia (IV PCA) (n = 22, F group) for postoperative 72 hours. The primary endpoint was the visual analogue scores (VAS) when coughing at postoperative 24 hours. Secondary end points were the VAS at 1, 6, 48, and 72 hours, time to first flatus, time to first rescue meperidine requirement, rescue meperidine consumption, length of hospital stay, postoperative nausea and vomiting, sedation, hypotension, dizziness, headache, and wound complications. RESULTS: The VAS at rest and when coughing were similar between the groups throughout the study. The time to first gas passage and time to first rescue meperidine at ward were significantly shorter in the R group compared to the F group (P = 0.010). Rescue meperidine was administered less in the R group; however, without statistical significance. Other study parameters were not different between the groups. CONCLUSIONS: Ropivacaine continuous infusion with an inverse ‘v ’ shaped bilateral, subfascial catheter placement showed significantly enhanced bowel recovery and analgesic efficacy was not different from IV PCA in LCRC surgery.
Analgesia
;
Analgesia, Patient-Controlled
;
Anesthetics, Local
;
Catheters
;
Colorectal Neoplasms*
;
Colorectal Surgery
;
Cough
;
Dizziness
;
Fentanyl
;
Flatulence
;
Headache
;
Humans
;
Hypotension
;
Laparoscopy
;
Length of Stay
;
Meperidine
;
Methods
;
Passive Cutaneous Anaphylaxis
;
Postoperative Nausea and Vomiting
;
Wounds and Injuries
5.The Influence of Iron Deficiency on Helicobacter pylori Eradication.
Sung Eun KIM ; Moo In PARK ; Seun Ja PARK ; Won MOON ; Jae Hyun KIM ; Kyoungwon JUNG ; Kwang Il SEO ; Seong Kyeong LIM ; Jin Kyu JUNG ; Hyeon Jin KIM ; Go Eun YEO ; Sung Chan JEON ; Duk Song CHO ; You Jin HAN
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2016;16(2):82-87
BACKGROUND/AIMS: Helicobacter pylori is a distinctive pathogen that lives in the gastric mucosa and is a well known risk factor of gastric adenocarcinoma. Iron deficiency aggravates the development of H. pylori-induced premalignant and malignant lesions in a cagA-dependent manner, enhancing H. pylori virulence. The aim of this study was to identify the relationship between iron deficiency and H. pylori eradication rates. MATERIALS AND METHODS: Participants who received 7 days of first-line triple therapy with serum iron level measured in parallel were retrospectively investigated between 2005 and 2014. H. pylori eradication was confirmed by the rapid urease test or 13C-urea breath test at least 4 weeks after completion of triple therapy. Iron deficiency was defined as either a serum iron level less than 50 µg/dL or a serum ferritin level less than 12 ng/mL. RESULTS: A total of 194 patients received 7 days of first-line triple therapy along with parallel serum iron level measurements over the 10-year period. The mean average age was 53.3 years (range, 21~86 years), and 135 patients (69.6%) were male. The overall H. pylori eradication rate was 83.5%. Proportions of eradication success with ferritin level less than 12 ng/mL and iron less than 50 µg/dL were 90.5% and 88.6%, respectively. However, there was no statistical difference in eradication rates according to iron deficiency. CONCLUSIONS: Iron deficiency might not be related with H. pylori eradication rates in this study. Further large-scale studies are needed to confirm this result.
Adenocarcinoma
;
Breath Tests
;
Disease Eradication
;
Ferritins
;
Gastric Mucosa
;
Helicobacter pylori*
;
Helicobacter*
;
Humans
;
Iron*
;
Male
;
Retrospective Studies
;
Risk Factors
;
Urease
;
Virulence